Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S Stintzing, L Miller-Phillips, D P Modest, et al.
Journal of Cancer Research and Clinical Oncology
|
May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
A Kurreck, M Geissler, U M Martens, et al.
ESMO Open
|
July 12, 2024
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial
A Ballhausen, M Karthaus, S Fruehauf, et al.
ESMO Open
|
August 15, 2022
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
ESMO Open
|
October 26, 2024
Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
ESMO Open
|
July 13, 2023
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
K Heinrich, M Karthaus, S Fruehauf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
D P Modest, I Ricard, S Stintzing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S Stintzing, P Wirapati, H-J Lenz, et al.
ESMO Open
|
May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
M Boukovala, D P Modest, I Ricard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method
M Haas, D T Waldschmidt, M Stahl, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S Stintzing, L Miller-Phillips, D P Modest, et al.
Journal of Cancer Research and Clinical Oncology
|
May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
A Kurreck, M Geissler, U M Martens, et al.
ESMO Open
|
July 12, 2024
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial
A Ballhausen, M Karthaus, S Fruehauf, et al.
ESMO Open
|
August 15, 2022
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
ESMO Open
|
October 26, 2024
Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
ESMO Open
|
July 13, 2023
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
K Heinrich, M Karthaus, S Fruehauf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
D P Modest, I Ricard, S Stintzing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S Stintzing, P Wirapati, H-J Lenz, et al.
ESMO Open
|
May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
M Boukovala, D P Modest, I Ricard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method
M Haas, D T Waldschmidt, M Stahl, et al.
Page
of 8